Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
February 22, 2021

Investigator-sponsored Phase II/III for Pfizer’s sirolimus for Sturge-Weber Syndrome sees 15-point surge in FDA regulatory potential

As of 15 February, the likelihood of approval (LoA) for Pfizer’s Rapamune (sirolimus) for Sturge-Weber Syndrome (SWS) rose 15 points, according to GlobalData’s LoA data.

By William Newton

As of 15 February, the likelihood of approval (LoA) for Pfizer’s Rapamune (sirolimus) for Sturge-Weber Syndrome (SWS) rose 15 points, according to GlobalData’s LoA data. The score was based on published results from an investigator-sponsored Phase II/III trial that saw sirolimus achieve a statistically significant improvement in one aspect of the primary endpoint.

The 10-patient Phase II/III) used change in cognitive functioning after six months as its primary outcome. The results were assessed using a panel of testing developed by SWS experts that included measures from the National Institute of Health Toolbox, according to The published data reported a statistically significant improvement in the Pattern Comparison Processing Speed Test, but did not show statistical significance in any other assessments in the primary endpoint, including in measures of executive function, attention, episodic memory, language skills, working memory, or patient-reported emotional functioning (Sebold A.J., et al. (2020) Paediatric Neurology 115: 29-40). Of the ten patients enrolled, one had a moderate upper respiratory infection possibly related to the drug while all other reported adverse events were mild.

While the LoA prior to this news was 8%, GlobalData’s analysis using a combination of machine learning and a proprietary algorithm has raised the LoA to 23%. Rapamune is currently marketed for kidney transplant rejection, angiofibroma and lymphangioleiomyomatosis.

William Newton is a Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy